Immunogenicity of haemophilus influenzae Type b Conjugate Vaccines in Korean Infants: A Meta-analysis

Journal of Korean Medical Science

Volumn 25, Issue 1, 2010, Pages 90-96

  Lee, Hyunju ^a   Hahn, Seokyung ^b   Lee, Hoan Jong ^b   Kim, Kyung Hyo ^b  

^a Ewha Womans University School of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Haemophilus influenzae type b; Immunity; Meta analysis; Vaccines

Indexed keywords

ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE VACCINE; HAEMOPHILUS VACCINE; TETANUS TOXOID; VACCINE;

ARTICLE; BACTERIAL MEMBRANE; CHEMISTRY; HUMAN; IMMUNOLOGY; INFANT; META ANALYSIS; METABOLISM; SOUTH KOREA;

ANTIBODIES; BACTERIAL CAPSULES; HAEMOPHILUS VACCINES; HUMANS; INFANT; REPUBLIC OF KOREA; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 77949327232     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.1.90     Document Type: Article

References (30)

1. Wenger JD, Ward WJ. Haemophilus influenzae vaccine. In: Plotkin SA, Orenstein WA, editors, Vaccines. 4th ed. Philadelphia: WB Saunders Co, 2004; 229-68.
2. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13: 302-17.
3. Heath PT. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J 1998; 17 (9 Suppl): S117-22.
4. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120: 184-9.
5. Obonyo CO, Lau J. Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis. Eur J Clin Microbiol Infect Dis 2006; 25: 90-7.
6. Eskola J, Kayhty H, Takala AK, Peltola H, Ronnberg PR, Kela E, Pekkanen E, McVerry PH, Makela PH. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990; 323: 1381-7.
7. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147: 1100.
8. Centers for Disease Control and Prevention (CDC). Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998-2000. MMWR Morb Mortal Wkly Rep 2002; 51: 234-7.
9. World Health Organization. WHO position paper on Haemophilus influenzae type b conjugate vaccines. (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record. Wkly Epidemiol Rec 2006; 81: 445-52.
10. Rossi IA, Zuber PL, Dumolard L, Walker DG, Watt J. Introduction of Hib vaccine into national immunization programmes: a descriptive analysis of global trends. Vaccine 2007; 25: 7075-80.
11. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990; 6: 5-30.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
13. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Metaanalyses. Lancet 1999; 354: 1896-900.
14. Choi SY, Kim HT, Kim YW, Kang YJ, Chung YC, Chang JK, Lee HJ. Immunogenicity of Haemophilus influenzae PRP-D conjugate vaccine in Korean infants. J Korean Pediatr Soc 1999; 42: 771-7.
15. Yoo ES, Park EA, Kim GH. Natural anti-PRP antibody levels of Haemophilus influenzae type b (Hib) and changes of antibody levels after three doses of vaccination. J Korean Pediatr Soc 1995; 38: 1201-9.
16. Kim JS, Cho SB, Lee HR, Park SK, Hwang PH. Immunogenicity and safety of Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) in Korean infants. Korean J Infect Dis 1996; 28: 225-32.
17. Chung EH, Kim YJ, Kim YK, Kim DH, Seo JW, Lee HJ. Immunogenicity and safety of a Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine (PTP-T; Hiberix™) in Korean infants. Korean J Pediatr Infect Dis 2003; 10: 71-9.
18. Kim KH, Lee H, Chung EH, Kang JH, Kim JH, Kim JS, Lee HJ, Oh SH, Park EA, Park SE. Immunogenicity and safety of two Haemophilus influenza type b conjugate vaccines in Korean infants. J Korean Med Sci 2008; 23: 929-36.
19. Yang PS, Seo JI, Noh KT, Yoo JH, Hwang KS, Hwang KG. Studies of the change of antibody titers after vaccination of Haemophilus influenzae PRP-T conjugate vaccine. J Korean Pediatr Soc 2002; 45: 987-93.
20. Chung EH, Ma SH, Hong YJ, Kim KH, Kim JH, Lee JA, Lee HJ. Immunogenicity and safety of a combined Hepatitis B and Haemophilus influenza Type b conjugate (PRP-OMP) vaccine (Comvax™; Merck & Co.) in Korean infants. Korean J Pediatr Infect Dis 2006; 13: 163-73.
21. Lagos R, Valenzuela MT, Levine OS, Losonsky GA, Erazo A, Wasserman SS, Levine MM. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet 1998; 351: 1472-6.
22. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, Weber M, Palmer A, Schneider G, Jobe K, Lahai G, Jaffar S, Secka O, Lin K, Ethevenaux C, Greenwood B. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349: 1191-7.
23. Santosham M, Wolff M, Reid R, Hohenboken M, Bateman M, Goepp J, Cortese M, Sack D, Hill J, Newcomer W, Capriotti L, Smith J, Owen M, Gahagan S, Hu D, Kling R, Lukacs L, Ellis RW, Vella PP, Calandra G, Matthews H, Ahonkhai V. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991; 324: 1767-72.
24. Peltola H, Aavitsland P, Hansen KG, Jonsdottir KE, Nokleby H, Romanus V. Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. J Infect Dis 1999; 179: 223-9.
25. Kurikka S, Kayhty H, Saarinen L, Ronnberg P, Eskola J, Makela PH. Comparison of five different vaccination schedules with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. J Pediatr 1996; 128: 524-30.
26. Kim JS, Jang YT, Kim JD, Park TH, Park JM, Kilgore PE, Kennedy WA, Park E, Nyambat B, Kim DR, Hwang PH, Kim SJ, Eun SH, Lee HS, Cho JH, Kim YS, Chang SJ, Huang HF, Clemens JD, Ward JI. Incidence of Haemophilus influenzae type b and other invasive diseases in South Korean children. Vaccine 2004; 22: 3952-62.
27. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology 2004; 113: 163-74.
28. Makela PH, Kayhty H, Leino T, Auranen K, Peltola H, Ekstrom N, Eskola J. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003; 22: 287-92.
29. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1984; 149: 1034-5.
30. Granoff DM. Assessing efficacy of Haemophilus influenzae type b combination vaccines. Clin Infect Dis 2001; 33 (Suppl 4): S278-87.